What Molecule Science Foundation does

Molecule Science Foundation, Inc. is a Delaware-incorporated nonprofit (501(c)(3) pending, EIN 41-4221270) headquartered in Dover, Delaware, that funds decentralized scientific research with a current focus on rare pediatric diseases. Its core operational model is community-funded grant-making: donors select a specific research project and contribute in $25 units via credit card or USDC stablecoins, receiving a community membership token (CRJDM Token or CRASD Token) that grants ongoing access to study progress, milestones, and published results. The foundation is currently sponsoring two IRB-approved studies conducted under the oversight of the Biomedical Research Alliance of New York (BRANY): the CRJDM Sub-Study for Juvenile Dermatomyositis, which uses ORyan Health's Artemis Platform for at-home capillary blood collection combined with single-cell RNA sequencing to generate JDM Immune Avatars, and the CRASD ASD Biomarker Sub-Study, which applies the BlueSavant AI RNA-based diagnostic model to at-home capillary blood samples for autism biomarker discovery. Approved budgets stand at $441,500 for CRJDM and $258,426 for CRASD, with a planned combined biospecimen collection of 200 samples (100 ASD plus 100 controls). The foundation is led by President & Treasurer Benjamin Snipes, Secretary & Director Aristotle Mannan, and Director Jeff Montgomery, and operates with no disclosed revenue, no headcount data, and no completed funding rounds. Beyond direct study sponsorship, MSF is building a publicly accessible library of legal and governance standards for decentralized science and distributes free educational materials on biotechnology and blockchain-enabled research as part of its public education mission.

Name

Molecule Science Foundation

Legal name

Molecule Science Foundation, Inc.

Website

https://moleculesciencefoundation.org

Company type

Private

Operating status

Operating

Short description

Molecule Science Foundation is a Delaware nonprofit (501(c)(3) pending) that funds decentralized scientific research on rare pediatric diseases through community donations, sponsoring IRB-approved at-home biospecimen studies for Juvenile Dermatomyositis and Autism Spectrum Disorder.

Ownership category

akta.pro rank

Product category

Nonprofit Research Funding

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

Keywords

• Decentralized science funding
• Rare pediatric disease research
• Biomarker discovery research
• Nonprofit research grants
• At-home biospecimen collection

Headquarters

HQ city

Dover

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Donations and Grants: The foundation operates as a 501(c)(3) pending nonprofit accepting tax-deductible donations in $25 units via credit card or USDC stablecoins. Donors receive community membership tokens as acknowledgment. Additional revenue comes from research grants and corporate sponsorships for sponsored studies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Molecule Science Foundation funds decentralized scientific research focused on rare pediatric diseases through community membership tokens and tax-deductible donations. It currently sponsors two IRB-approved studies: the CRJDM Token Sub-Study (Juvenile Dermatomyositis, $441,500 approved budget) using single-cell RNA sequencing of at-home blood samples, and the CRASD Token Sub-Study (Autism Spectrum Disorder, $258,426 approved budget) using the BlueSavant AI RNA-based diagnostic model. Donors contribute in $25 units via credit card or USDC and receive community membership tokens that connect them to study progress and published results.

Product overview

Molecule Science Foundation operates as a single unified nonprofit research funding platform rather than a multi-module product suite. The organization funds two active research programs—Juvenile Dermatomyositis (JDM) and Autism Spectrum Disorder (ASD)—through community membership tokens (CRJDM Token and CRASD Token). Donors contribute in $25 units via credit card or USDC, receiving tokens that grant membership in the respective research communities. Both studies utilize at-home pediatric biospecimen collection (via ORyan Health's Artemis Platform), with the JDM study employing single-cell RNA sequencing and the ASD study using the BlueSavant AI RNA-based diagnostic model.

Differentiator

Problem solved

Functional benefit

Brands

• CRJDM Token: A community membership token supporting MSF's sponsored Juvenile Dermatomyositis (JDM) Sub-Study, which uses at-home blood collection and single-cell RNA sequencing to generate JDM Immune Avatars.
• CRASD Token

Products and services

• CRJDM Token

Quantifiable outcome

• 200 biospecimen samples collected via at-home method
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Biomedical Research Alliance of New York (BRANY)coreStrategic or Co-development PartnerBRANY provides IRB approval and oversight for both MSF-sponsored studies (CRJDM and CRASD). This partnership ensures all research conducted under MSF's funding meets regulatory and ethical standards for human subjects research, including pediatric studies involving at-home biospecimen collection.
• ORyan Health (Artemis Platform)coreTechnology or IntegrationORyan Health provides the Artemis Platform used for at-home pediatric biospecimen collection in both JDM and ASD studies. This technology enables families to collect blood samples at home, eliminating the need for clinical visits and expanding geographic accessibility of research participation.
• BlueSavant AIcoreTechnology or IntegrationBlueSavant AI provides the RNA-based diagnostic model used in the ASD Biomarker Sub-Study. This AI-powered model analyzes capillary blood samples collected at home to identify potential autism biomarkers, advancing early detection research for Autism Spectrum Disorder.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• VitaDAO: A DeSci DAO using tokenized community funding to finance longevity and early-stage biomedical research. Comparable to MSF as a peer decentralized science organization using crypto-native rails to fund specific research programs.
• Cure JM Foundation: A 501(c)(3) nonprofit specifically dedicated to Juvenile Myositis (including JDM) research and family support. Directly comparable to MSF's CRJDM program in disease focus, mission, and nonprofit research-funding model.
• Cure SMA: A 501(c)(3) nonprofit funding Spinal Muscular Atrophy research and family support. Comparable to MSF as a rare pediatric disease research funding organization operating branded research programs and community-driven fundraising.
• Autism Research Institute: A nonprofit funding and disseminating ASD research, with a focus on evidence-based biological and biomedical approaches. Directly comparable to MSF's CRASD program in mission and operating model for autism research funding.
• Molecule DAO: A decentralized autonomous organization funding early-stage drug discovery through token-based community funding. Closely comparable to MSF in combining Web3/crypto-native financing with biotech research, sharing the broader DeSci mission and operating model.
• The Myositis Association: A national nonprofit funding research and providing support across the myositis disease spectrum, including juvenile dermatomyositis. Comparable to MSF in operating a multi-program rare disease research funding model for the same patient population.

Broad incumbents

• National Organization for Rare Disorders (NORD): The umbrella US nonprofit for the rare disease community, operating research grants, advocacy, and patient registries across hundreds of conditions. Comparable to MSF in mission (rare disease research and support) but at vastly greater scale and breadth.
• Autism Speaks: One of the largest ASD-focused nonprofits, funding a broad portfolio of autism research, advocacy, and services. Overlaps with MSF's CRASD program in disease focus but operates at much greater scale across a wider mandate.
• EveryLife Foundation for Rare Diseases: A rare disease policy and advocacy nonprofit advancing legislation and biomedical research funding across the orphan disease space. Comparable to MSF in addressing rare disease research funding barriers at a systemic level.

Emerging players

• LabDAO: A DeSci organization coordinating distributed biotech wet-lab services via tokenized incentives. Compares to MSF as a peer DeSci entity applying Web3 coordination mechanisms to scientific research infrastructure, though focused on lab services rather than disease-specific funding.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecule Science Foundation